Human Prealbumin (Transthyretin, TTR) AssayMax ELISA KitHuman Prealbumin (Transthyretin, TTR) AssayMax ELISA Kit
Move your mouse over image or click to enlarge

Human Prealbumin (Transthyretin, TTR) AssayMax ELISA Kit

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.

Cat# Size Price Qty Buy
EP3010-1 96 Well Plate £260.00

Additional Information

Property Value or Rating
Manufacturer Assaypro, LLC.
Product Type AssayMax™ ELISA Kits
Samples Serum, Urine, Saliva, Milk, Cell Culture, CSF
Species Human
Reactivity Human
Assay Format Sandwich ELISA
Product Size 96 Well Plate
Range 0.122-31.25 ng/ml
Plex Number 1
Storage Refer to component labels for details
Entrez Gene 7276
Omim 176300
UniProt P02766
UniGene Hs.427202
Special Notes For Research Use Only, Not To Be Used For Diagnostic Purposes
References * Escher N et al. (2007) Posttranslational Modifications of Transthyretin Are Serum Markers in Patients with Mycosis Fungoides1. Neoplasia. 9(3): 254-259 
* Maheshwari A et al. (2009) Developmental changes in circulating IL-8/CXCL8 isoforms in neonates. Cytokine. 46(1):12-16 
* Wang FE et al (2010) MicroRNA-204/211 alters epithelial physiology. FASEB J. 24(5):1552-1571 
* Alvarez R et al. (2011) Sirna therapy for transthyretin (ttr) related ocular amyloidosis. Patent application: CA 2792291 A1 
* Mastricci AL et al. (2011) Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11 
* Perrin RJ et al. (2011) Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PloSOne Jan 12; 6(1):e16032 
* Sah D (2011) Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR). WIPO Patent Application US2010/055311 
* Wang F and Miller S (2011) Mir 204, mir 211, their anti-mirs, and therapeutic uses of same. USPTO Patent Applicaton 20110190378
* Alvarez R et al. (2012) Compositions and methods for inhibiting expression of transthyretin. Patent number: US8168775 B2 
* Velayudhan L et al. (2012) Plasma Transthyretin as a Candidate Marker for Alzheimer 
* Tsui H (2014) Neuropsychological and plasma biomarkers for detecting Alzheimer's disease. Brain Health Research Center. 
* Zhu L et al. (2014) Transthyretin as a novel candidate biomarker for preeclampsia. Exp Ther Med.7(5):1332-1336. Epub 2014 Feb 18 
* Pasella S (2015) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 2015 May 21 
* Kallanthottathil R et al. (2016) RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES. Patent: US9399775 B2, PCT/US2012/065691. 
* Pasella S et al. (2016) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 28(1):77-82 
* Ando Y et al. (2017) siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis. United States patent application: 20170096663 A1 

" title="

* Escher N et al. (2007) Posttranslational Modifications of Transthyretin Are Serum Markers in Patients with Mycosis Fungoides1. Neoplasia. 9(3): 254-259 
* Maheshwari A et al. (2009) Developmental changes in circulating IL-8/CXCL8 isoforms in neonates. Cytokine. 46(1):12-16 
* Wang FE et al (2010) MicroRNA-204/211 alters epithelial physiology. FASEB J. 24(5):1552-1571 
* Alvarez R et al. (2011) Sirna therapy for transthyretin (ttr) related ocular amyloidosis. Patent application: CA 2792291 A1 
* Mastricci AL et al. (2011) Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11 
* Perrin RJ et al. (2011) Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PloSOne Jan 12; 6(1):e16032 
* Sah D (2011) Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR). WIPO Patent Application US2010/055311 
* Wang F and Miller S (2011) Mir 204, mir 211, their anti-mirs, and therapeutic uses of same. USPTO Patent Applicaton 20110190378
* Alvarez R et al. (2012) Compositions and methods for inhibiting expression of transthyretin. Patent number: US8168775 B2 
* Velayudhan L et al. (2012) Plasma Transthyretin as a Candidate Marker for Alzheimer 
* Tsui H (2014) Neuropsychological and plasma biomarkers for detecting Alzheimer's disease. Brain Health Research Center. 
* Zhu L et al. (2014) Transthyretin as a novel candidate biomarker for preeclampsia. Exp Ther Med.7(5):1332-1336. Epub 2014 Feb 18 
* Pasella S (2015) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 2015 May 21 
* Kallanthottathil R et al. (2016) RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES. Patent: US9399775 B2, PCT/US2012/065691. 
* Pasella S et al. (2016) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 28(1):77-82 
* Ando Y et al. (2017) siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis. United States patent application: 20170096663 A1 

" target="_blank">

* Escher N et al. (2007) Posttranslational Modifications of Transthyretin Are Serum Markers in Patients with Mycosis Fungoides1. Neoplasia. 9(3): 254-259 
* Maheshwari A et al. (2009) Developmental changes in circulating IL-8/CXCL8 isoforms in neonates. Cytokine. 46(1):12-16 
* Wang FE et al (2010) MicroRNA-204/211 alters epithelial physiology. FASEB J. 24(5):1552-1571 
* Alvarez R et al. (2011) Sirna therapy for transthyretin (ttr) related ocular amyloidosis. Patent application: CA 2792291 A1 
* Mastricci AL et al. (2011) Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11 
* Perrin RJ et al. (2011) Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PloSOne Jan 12; 6(1):e16032 
* Sah D (2011) Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR). WIPO Patent Application US2010/055311 
* Wang F and Miller S (2011) Mir 204, mir 211, their anti-mirs, and therapeutic uses of same. USPTO Patent Applicaton 20110190378
* Alvarez R et al. (2012) Compositions and methods for inhibiting expression of transthyretin. Patent number: US8168775 B2 
* Velayudhan L et al. (2012) Plasma Transthyretin as a Candidate Marker for Alzheimer 
* Tsui H (2014) Neuropsychological and plasma biomarkers for detecting Alzheimer's disease. Brain Health Research Center. 
* Zhu L et al. (2014) Transthyretin as a novel candidate biomarker for preeclampsia. Exp Ther Med.7(5):1332-1336. Epub 2014 Feb 18 
* Pasella S (2015) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 2015 May 21 
* Kallanthottathil R et al. (2016) RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES. Patent: US9399775 B2, PCT/US2012/065691. 
* Pasella S et al. (2016) Plasma concentrations of transthyretin in older Sardinians including centenarians. Aging Clin Exp Res. 28(1):77-82 
* Ando Y et al. (2017) siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis. United States patent application: 20170096663 A1 

Related Documents